Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16009661 | 1.00 | PTGS2 (0.53) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL16017874 | 0.96 | PTGS2 (0.52) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL16010034 | 0.95 | PTGS2 (0.53) | PTGS2HTR1APKMPTGS1GLO1 | |
| Tobramycin SCHEMBL16011782 | 0.90 | PTGS2 (0.55) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL26194400 | 0.72 | PTGS2 (0.57) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL19376389 | 0.72 | PTGS2 (0.84) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL14031839 | 0.72 | PTGS2 (0.84) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL4549122 | 0.72 | PTGS2 (1.00) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL13067493 | 0.71 | PTGS2 (0.69) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL29855593 | 0.71 | PTGS2 (0.86) | PTGS2HTR1APKMPTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014138343-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |